Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Parkinson's disease diagnosis confirmed by a neurologist specializing in movement disorders~2. Insufficient criteria for a diagnosis of Irritable Bowel Syndrome~3. Constipation for over 6 months, unresponsive to Milk of Magnesia, and requiring at least weekly treatment using an oral laxative, stool softener, bulking agent, and/or a suppository, and dissatisfaction with current treatment.~4. Body Mass Index is 18-40 kg/m2~5. At least 2 of the Rome IV functional constipation criteria are met~6. Loose stools are rarely present without the use of laxatives~7. Patient is willing and able to sign informed consent and comply with all study procedures~8. Patients must be able to read, understand, and accurately record data into the diary to guarantee full participation in the study~   Females only:~9. Must have negative serum or urine pregnancy tests and must not be lactating~10. If of child-bearing age: Must agree to using a hormonal (i.e., oral, implantable, or injectable) and either single- or double-barrier method of birth control throughout the study period. A vasectomized partner will be allowed as one in conjunction with another single-barrier method.~11. If unable to have children: Must have this documented in the case report form (i.e., ubal ligation, hysterectomy, or post-menopausal \[defined as a minimum of one year since last menstrual period\]). Post-menopausal status will be confirmed by follicle stimulating hormone in women less than 60 years of age.~Exclusion Criteria:~1. Unable or unwilling to provide informed consent or to comply with study procedures~2. Diagnosis of secondary constipation beyond that of PD~3. Structural or metabolic diseases that affect the GI system~4. Functional GI disorder~5. Unable or unwilling to withdraw from taking the following medications 2 weeks prior to the dose-escalation period and throughout the study: Laxatives, opiates, sedatives, hypnotics, anti-histamines, protein pump inhibitors or any medications which may cause constipation~6. History of recent major surgery (within 60 days of screening)~7. Any clinically significant abnormalities on screening laboratories or physical examination as determined by the Investigator~8. Neurological disorder other than PD~9. On treatment with intra-jejunal dopamine~10. Treatment with COMT inhibitors for fewer than 4 weeks (entacapone, tolcapone, Stalevo)~11. Unable to maintain a stable diet regimen~12. Patients with a cognitive impairment that preclude them from understanding the informed consent~13. Patients placed under legal guardianship~14. Acute GI illness within 48 hours of the baseline period~15. History of major GI surgery (e.g. previous abdominal surgery, including cholecystectomy), except that patients with uncomplicated appendectomy are allowed~16. ALT or AST \> 1.5 X upper limit of normal (ULN) during screening~17. Females who are pregnant or breastfeeding~18. History of excessive alcohol use or substance abuse~19. Patient or caregiver unable to administer daily oral dosing~20. Participation in an investigational clinical study within the 6 months prior to dosing in the present study~21. Any other reason, which in the opinion of the Investigator would confound proper interpretation of the study

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 86 Years
- Healthy Volunteers: f

Study Arms:
- ENT-01 (Type: EXPERIMENTAL): ENT-01 at a to-be-determined dose taken by mouth every day upon awakening.
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Placebo to be taken by mouth every day upon awakening

Based on this trial design, predict the completion outcome and termination type (if applicable).